Patent ID: 11858995
Assignee: GENMAB A/S
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 10:
11. The method of claim 1, wherein the bispecific antibody is administered in 28-day cycles, wherein:
a) in cycle 1, a priming dose is administered on day 1, an intermediate dose on day 8, and a full dose of 12-60 mg on days 15 and 22;
b) in cycles 2-3, a full dose of 12-60 mg is administered on days 1, 8, 15, and 22;
c) in cycles 4-9, a full dose of 12-60 mg is administered on days 1 and 15; and
d) in cycle 10 and subsequent cycles, a full dose of 12-60 mg is administered on day 1.